4//SEC Filing
MCCORMICK FRANK 4
Accession 0001470831-25-000282
CIK 0001743881other
Filed
Oct 30, 8:00 PM ET
Accepted
Oct 31, 4:38 PM ET
Size
14.0 KB
Accession
0001470831-25-000282
Insider Transaction Report
Form 4
MCCORMICK FRANK
Director
Transactions
- Sale
Common Stock
2025-10-29$65.48/sh−111,755$7,317,315→ 766,583 total(indirect: By Trust) - Sale
Common Stock
2025-10-29$68.50/sh−8,598$588,985→ 723,372 total(indirect: By Trust) - Sale
Common Stock
2025-10-29$66.20/sh−31,116$2,059,749→ 735,467 total(indirect: By Trust) - Sale
Common Stock
2025-10-29$67.52/sh−3,497$236,130→ 731,970 total(indirect: By Trust) - Sale
Common Stock
2025-10-29$69.24/sh−43,393$3,004,349→ 679,979 total(indirect: By Trust)
Holdings
- 83,275
Common Stock
Footnotes (6)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.
- [F2]Represents the weighted average sale price of the shares sold from $65.00 to $65.999 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F3]Represents the weighted average sale price of the shares sold from $66.00 to $66.9875 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F4]Represents the weighted average sale price of the shares sold from $67.00 to $67.996 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F5]Represents the weighted average sale price of the shares sold from $68.005 to $68.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F6]Represents the weighted average sale price of the shares sold from $69.00 to $69.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
Related Parties
1- filerCIK 0001257809
Filing Metadata
- Form type
- 4
- Filed
- Oct 30, 8:00 PM ET
- Accepted
- Oct 31, 4:38 PM ET
- Size
- 14.0 KB